OCGN Ocugen, Inc.
$1.00▼ -5.44%
Healthcare
Other
Volume 3.14M
Avg Volume (10D) 9.46M
Key Metrics & Fundamentals
Market Cap
$339.89M
P/E Ratio
–
Div Yield
–%
52W Range
0.99 - 2.73
% vs 50 MA
-19.91%
% vs 200 MA
-29.76%
RSI-14
31.8
MACD Histogram
-0.0400
Beta (1Y vs SPY)
1.47
Free Cash Flow
-$12.22M
Gross Rev
$1.49M
Gross Profit
$1.49M
EBITDA
-$15.54M
COGS
–
Operating Exp
$17.93M
Operating Income
-$16.44M
EBIT
-$16.44M
Pretax Income
-$24.88M
Net Income
-$24.88M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Ocugen Insider Sold Shares Worth $589,110, According to a Recent SEC Filing
MT Newswires · Sep 14, 2026 8:32 AM
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Zacks · Sep 2, 2026 2:52 PM
Ocugen Doses First Patient in Trial of Potential Eye Disease Drug
MT Newswires · Sep 1, 2026 11:35 AM
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire · Sep 1, 2026 11:02 AM
Ocugen to Participate in Upcoming September Investor and Industry Conferences
GlobeNewswire · Aug 25, 2026 11:02 AM
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
MarketBeat · Aug 16, 2026 1:01 AM
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 6:14 PM
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Zacks · Aug 7, 2026 5:18 PM
Ocugen Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 6:04 AM
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ...
GuruFocus.com · Aug 6, 2026 11:15 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See OCGN's money flow as a full page
Social Sentiment
Avg +0.66 · 10 posts
NewsDiscussionPriceTargetMaybe Put OCGN On Your Watchlist
r/options · Sep 18, 2025
The post highlights potential upside, a bullish chart signal, and a high-risk/high-reward investment opportunity.
positive
+0.30
NewsDDOcugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea
r/wallstreetbets · Jun 5, 2025
The news of a licensing deal is generally a positive development for the company's future prospects.
positive
+0.60
DDNewsEarningsTrade$OCGN earnings on 8/11, next week presentation at Nasdaq plaza, SI increased, this is ready to moon!!!! 🚀🚀🚀🚀🚀🚀🚀💎👐
r/wallstreetbets · Nov 7, 2024
The author expresses strong bullish sentiment and highlights catalysts for the stock's potential growth.
very_positive
+0.80
TradeDiscussionThe Wild Ride of a Decade in Trading: To Continue or Not?
r/wallstreetbets · Nov 4, 2024
The author details a successful trade with OCGN, indicating positive sentiment.
positive
+0.70
DDTradeNewsPriceTarget$OCGN the best next moon out there? 🚀🚀🚀🚀
r/wallstreetbets · Oct 29, 2024
The author expresses strong bullish sentiment, referencing short interest, R&D focus, and a significant catalyst event.
very_positive
+0.90
Page 1 of 2 (10 total)
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.